The Recall Desk

Manufacturer

Attix Pharmaceuticals

470 recalls in our database name Attix Pharmaceuticals as the manufacturing or recalling firm.

What the numbers show

Total
470
Critical
0
Severe
378
Most recent
2015-04-29

Of the 470 recalls from Attix Pharmaceuticals we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 378 (80%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

376–400 of 470

  • SevereFDA (Drugs)·D-960-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zonisamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Zonisamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Zonisamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-944-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trifluridine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trifluridine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trifluridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-515-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aminopyridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Aminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-614-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dapsone API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dapsone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Dapsone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-833-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paroxetine Active Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling paroxetine active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Paroxetine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-507-2015·2015-04-29

    Aldosterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Aldosterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aldosterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-914-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tamsulosin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tamsulosin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tamsulosin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-528-2015·2015-04-29

    Atovaquone API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Atovaquone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Atovaquone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-522-2015·2015-04-29

    Attix Pharmaceuticals Recalls Anastrozole API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Anastrozole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Anastrozole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-543-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bimatoprost API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bimatoprost active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bimatoprost active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-582-2015·2015-04-29

    Cholestyramine API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Cholestyramine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cholestyramine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-688-2015·2015-04-29

    Flurbiprofen API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling flurbiprofen active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flurbiprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-734-2015·2015-04-29

    Irbesartan API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Irbesartan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Irbesartan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-666-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etoposide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etoposide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Etoposide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-778-2015·2015-04-29

    Attix Pharmaceuticals Recalls Memantine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Memantine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Memantine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-958-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zoledronic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Zoledronic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Zoledronic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-839-2015·2015-04-29

    Attix Pharmaceuticals Recalls Phenolphthalein Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Phenolphthalein active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Phenolphthalein active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-613-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dapiprazole HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dapiprazole HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Dapiprazole HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-935-2015·2015-04-29

    Tolvaptan API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tolvaptan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tolvaptan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-939-2015·2015-04-29

    Tranilast API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Tranilast active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tranilast active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-630-2015·2015-04-29

    Attix Pharmaceuticals Recalls Digoxin Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Digoxin active pharmaceutical ingredient repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Digoxin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-492-2015·2015-04-29

    Attix Pharmaceuticals Recalls 4-Aminopyridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 4-Aminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    4-Aminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-884-2015·2015-04-29

    Attix Pharmaceuticals Recalls Roflumilast API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Roflumilast active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Roflumilast active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-579-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloroquine Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloroquine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloroquine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-669-2015·2015-04-29

    Attix Pharmaceuticals Recalls Exemestane API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Exemestane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The product was distributed nationwide to compounding pharmacies and research organizations.

    Product
    Exemestane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide